Description
Cerebrospinal fluid amyloid beta 42, total tau, and phosphorylated tau 181 are well accepted markers of Alzheimer’s disease. These biomarkers better reflect disease pathogenesis compared to clinical diagnosis. Identifying genes/loci that regulate the levels of these biomarkers can help us uncover novel biological pathways involved in the disease mechanism. We performed a GWAS meta-analysis including 18,948 individuals of European ancestry from 30 different cohorts, including the Knight-ADRC, ADNI, DIAN, ALFA+, EADB among others. This is the largest study to date for the three CSF biomarkers.